Tokyo-based Astellas Pharma and South San Francisco-based Sutro Biopharma have inked a global collaboration and licensing deal aimed at the discovery and development of novel immunostimulatory antibody-drug conjugates (iADCs).
https://www.pharmalive.com/wp-content/uploads/2022/06/BioSpacehandshake6-27-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-06-28 11:17:462022-06-28 13:11:18Astellas and Sutro unite to overcome checkpoint inhibitor limitations with iADCs
